Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Total Non-Current Liabilities: 2020-2024

Historic Total Non-Current Liabilities for Mirum Pharmaceuticals (MIRM) over the last 5 years, with Dec 2024 value amounting to $442.6 million.

  • Mirum Pharmaceuticals' Total Non-Current Liabilities rose 10.46% to $477.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $477.1 million, marking a year-over-year increase of 10.46%. This contributed to the annual value of $442.6 million for FY2024, which is 12.31% up from last year.
  • Mirum Pharmaceuticals' Total Non-Current Liabilities amounted to $442.6 million in FY2024, which was up 12.31% from $394.1 million recorded in FY2023.
  • Mirum Pharmaceuticals' 5-year Total Non-Current Liabilities high stood at $442.6 million for FY2024, and its period low was $21.1 million during FY2020.
  • In the last 3 years, Mirum Pharmaceuticals' Total Non-Current Liabilities had a median value of $394.1 million in 2023 and averaged $302.4 million.
  • Data for Mirum Pharmaceuticals' Total Non-Current Liabilities shows a peak YoY soared of 458.87% (in 2023) over the last 5 years.
  • Mirum Pharmaceuticals' Total Non-Current Liabilities (Yearly) stood at $21.1 million in 2020, then soared by 110.80% to $44.5 million in 2021, then soared by 58.41% to $70.5 million in 2022, then spiked by 458.87% to $394.1 million in 2023, then climbed by 12.31% to $442.6 million in 2024.